Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.
Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.